StemCell Therapy

Stem Cells Used in the USA !!!

Read more:
Stem Cell Therapy for Peripheral Artery Disease

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth of Research Product Sales

International Stem Cell Corporation (OTCBB: ISCO) (ISCO) announces that revenue in the first quarter of 2011 was $1.5 million, compared with revenue of $273,000 in the first quarter of 2010. The increase was primarily due to $1.1 million in sales of Lifeline Skin Care products achieved in the pilot direct-to-consumer launch. Adding to the revenue growth was a 35% increase over the prior year in sales of human cell culture research products from subsidiary Lifeline Cell Technology.

ISCO also disclosed that it is delaying the filing of its Report on Form 10-Q for the period ending March 31, 2011 in order to resolve an accounting question as described below.

Shortly before the scheduled date for filing the 10-Q, ISCO identified an issue related to whether a technical interpretation of certain accounting guidance found in FASB ASC Topic 815, Derivatives and Hedging could require a change in the manner ISCO has historically accounted for the value of warrants originally issued as compensation to brokers working for the placement agent in the Company's 2007 initial public offering.

The accounting question is highly technical in nature and would have no impact on cash or revenues, but relates solely to the non-cash accounting for warrants issued several years ago. Rather than publish information that might be subject to further revision, ISCO has elected to delay the filing of its 10-Q until a decision can be made as to whether or not adjustments will need to be made and, if so, exactly what the accounting entries will be. The Company is committed to resolving this question as promptly as possible and will disclose the conclusion in the 10-Q.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated resolution of the accounting question, and opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, the application of accounting guidance, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth of Research Product Sales

International Stem Cell Corporation (OTCBB: ISCO) (ISCO) announces that revenue in the first quarter of 2011 was $1.5 million, compared with revenue of $273,000 in the first quarter of 2010. The increase was primarily due to $1.1 million in sales of Lifeline Skin Care products achieved in the pilot direct-to-consumer launch. Adding to the revenue growth was a 35% increase over the prior year in sales of human cell culture research products from subsidiary Lifeline Cell Technology.

ISCO also disclosed that it is delaying the filing of its Report on Form 10-Q for the period ending March 31, 2011 in order to resolve an accounting question as described below.

Shortly before the scheduled date for filing the 10-Q, ISCO identified an issue related to whether a technical interpretation of certain accounting guidance found in FASB ASC Topic 815, Derivatives and Hedging could require a change in the manner ISCO has historically accounted for the value of warrants originally issued as compensation to brokers working for the placement agent in the Company's 2007 initial public offering.

The accounting question is highly technical in nature and would have no impact on cash or revenues, but relates solely to the non-cash accounting for warrants issued several years ago. Rather than publish information that might be subject to further revision, ISCO has elected to delay the filing of its 10-Q until a decision can be made as to whether or not adjustments will need to be made and, if so, exactly what the accounting entries will be. The Company is committed to resolving this question as promptly as possible and will disclose the conclusion in the 10-Q.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated resolution of the accounting question, and opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, the application of accounting guidance, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

see http://www.cellmedicine.com

More:
Stem Cell Therapy for Rheumatoid Arthritis

What would Your Life be Like if You Had Less Wrinkles?

See original here:
Stem Cell Therapy Cream: Less Wrinkles In 30 Days or Less Anti-Wrinkle Cream That Works

Visit: tinyurl.com for more pet stories -- A new technique for fighting the crippling effects of severe hip dysplasia is catching the attention of many large breed dog owners. Anne Marie Ogle of Napanoch, the owner of Dasha, a 9 year-old German Shepherd, hopes stem cell therapy will improve her pet's quality of life.

Visit link:
Dogged by pain -- stem cell therapy for dogs

CARLSBAD, Calif. -- (May 19, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, has now enrolled the first U.S.-based donor in its program to establish a bank of clinical-grade human parthenogenetic stem cells (hpSCs) capable of being immune-matched to millions of patients.

Dr. Simon Craw, Vice President of ISCO with primary responsibility for building its UniStemCell Bank, said, “Enrolling our first donor is a key milestone towards our goal of creating a bank of clinical-grade pluripotent human stem cells with the ability to immune-match millions of patients. It is extremely exciting to start this new phase of development, and I look forward to making new clinical-grade hpSC lines available to medical researchers around the world.”

ISCO maintains the world’s largest collection of research-grade human parthenogenetic stem cell (hpSC) lines which it uses along with its partners and collaborators to investigate cellular therapies for a number of incurable human diseases.

ISCO previously announced it had successfully obtained the necessary regulatory approvals for obtaining human oocytes, including Institutional Review Board (IRB) approval and Stem Cell Research Oversight (SCRO) committee approval. Today’s announcement marks the next phase of development as the Company is now positioned to begin producing new clinical-grade hpSC lines.

These new cell lines will be ISCO’s first hpSCs to be produced in the United States in accordance with Good Manufacturing Practice (cGMP) specifications. The new cGMP hpSC lines will be uniquely valuable in therapeutic research and clinical development as cells or tissue derived from such cells can be used in human clinical trials.

ISCO’s scientific discoveries have resulted in the development of a unique new type of pluripotent stem cells that possess a number of distinct advantages over other types of human pluripotent stem cells. ISCO uses unfertilized oocytes to create human “parthenogenetic” stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential production and benefits of stem cell lines, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

760-940-6383

Kenneth C. Aldrich

Chairman

kaldrich@intlstemcell.com

Simon Craw, Ph.D.

Vice President

sc@intlstemcell.com

or:

Lippert/Heilshorn & Associates

Don Markley (dmarkley@lhai.com)

310-691-7100

# # #

International Stem Cell Corporation Chairman Comments on UC San Diego Study That Finds Therapies Using Induced Pluripotent Stem Cells Could Encounter Immune Rejection Problems

Scientists at the University of California, San Diego, announced last week that they had discovered that the class of stem cells known as "induced pluripotent stem cells" or "iPS" cells could cause an immune rejection problem when transplanted into mice. Scientists had hoped that these cells would have two big advantages over embryonic stem cells: they would not be controversial because their creation did not entail the destruction of human embryos; and, since the stem cells could be made from a particular patient’s skin cells, they could be used to make tissues that would not be rejected by the patient’s own immune system. Although responses in humans may be different, the discovery of an immune response in mice suggests that the second of these hopes may not be so easily realized.

That is disappointing news in many ways, but it illustrates what we at International Stem Cell Corporation (ISCO) think will be one of the great benefits of the Parthenogenetic Stem Cells our scientists have created and patented.

Parthenogenetic stem cells are not only pluripotent they also do not involve any destruction or damage to a viable human embryo. Since they are never fertilized (and can't become a child) they carry the DNA of only the egg donor and not the added DNA of a father or other sperm donor. This results in the possibility of matching these cells to large groups of people without causing immune response problems.

The science is a bit complicated, but the result is illustrated by the fact that the very first stem cell line ISCO created using its newest techniques has the potential to match the immune systems of over 50 million people. With the right donors, cell lines from as few as 50 donors (one respected scientist has said as few as 10 donors) could match a very large portion of the world's population. There is a lot of work yet to be done, but if one thinks of it as comparable to a blood bank, but for stem cells instead, the concept becomes quite exciting.

Lastly, even if iPS cells are never used for transplant therapy, they still have wonderful research potential, so those who hoped for medical breakthroughs using them should not despair. They are, and will be, very important, even though there are better pathways to transplant therapy.

Kenneth C. Aldrich - Chairman

International Stem Cell Corporation

Source: Press Release from the University of California San Diego http://www.eurekalert.org/pub_releases/2011-05/uoc--sft051211.php

ISCO Scientists to Present Results of Recent Stem Cell Research on Central Nervous System and Liver Diseases at Annual Meeting of American Society of Gene and Cell Therapy

International Stem Cell Corporation (OTCBB: ISCO) announced today that two of its leading scientists, Vice President Dr. Ruslan Semechkin and Director of Research and Therapeutic Development Dr. Nikolay Turovets, will present the results of their most recent experiments on the therapeutic use of human parthenogenetic stem cells (hpSCs) at the 14th Annual Meeting of American Society of Gene and Cell Therapy in Seattle.

ISCO's breakthrough discoveries have resulted in a new type of pluripotent human stem cells with distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells. Like embryonic stem cells, hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike embryonic stem cells, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.

The data presented at the Seattle conference represents progress made in two specific areas: 1) the successful derivation of neuronal stem cell lines, which can potentially be used for treatment of degenerative diseases of the central nervous system (CNS), and 2) the differentiation of hpSCs towards liver cells and their progenitors.

Dr. Semechkin's oral presentation titled "Neural Stem Cells of Parthenogenetic Origin" will be on Thursday, May 19, 2011 at 4:15 pm.

Dr. Turovets poster presentation titled "An in vitro Analog of the Primitive Streak to Derive High-Purity Definitive Endoderm Lineages Uncontaminated with Undifferentiated Cells" will be on Saturday, May 21, 2011.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO & President, Lifeline Skin Care
ras@intlstemcell.com
Or:
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

International Stem Cell Corporation Chairman Comments on UC San Diego Study That Finds Therapies Using Induced Pluripotent Stem Cells Could Encounter Immune Rejection Problems

Scientists at the University of California, San Diego, announced last week that they had discovered that the class of stem cells known as "induced pluripotent stem cells" or "iPS" cells could cause an immune rejection problem when transplanted into mice. Scientists had hoped that these cells would have two big advantages over embryonic stem cells: they would not be controversial because their creation did not entail the destruction of human embryos; and, since the stem cells could be made from a particular patient’s skin cells, they could be used to make tissues that would not be rejected by the patient’s own immune system. Although responses in humans may be different, the discovery of an immune response in mice suggests that the second of these hopes may not be so easily realized.

That is disappointing news in many ways, but it illustrates what we at International Stem Cell Corporation (ISCO) think will be one of the great benefits of the Parthenogenetic Stem Cells our scientists have created and patented.

Parthenogenetic stem cells are not only pluripotent they also do not involve any destruction or damage to a viable human embryo. Since they are never fertilized (and can't become a child) they carry the DNA of only the egg donor and not the added DNA of a father or other sperm donor. This results in the possibility of matching these cells to large groups of people without causing immune response problems.

The science is a bit complicated, but the result is illustrated by the fact that the very first stem cell line ISCO created using its newest techniques has the potential to match the immune systems of over 50 million people. With the right donors, cell lines from as few as 50 donors (one respected scientist has said as few as 10 donors) could match a very large portion of the world's population. There is a lot of work yet to be done, but if one thinks of it as comparable to a blood bank, but for stem cells instead, the concept becomes quite exciting.

Lastly, even if iPS cells are never used for transplant therapy, they still have wonderful research potential, so those who hoped for medical breakthroughs using them should not despair. They are, and will be, very important, even though there are better pathways to transplant therapy.

Kenneth C. Aldrich - Chairman

International Stem Cell Corporation

Source: Press Release from the University of California San Diego http://www.eurekalert.org/pub_releases/2011-05/uoc--sft051211.php

CARLSBAD, Calif. -- (May 19, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, has now enrolled the first U.S.-based donor in its program to establish a bank of clinical-grade human parthenogenetic stem cells (hpSCs) capable of being immune-matched to millions of patients.

Dr. Simon Craw, Vice President of ISCO with primary responsibility for building its UniStemCell Bank, said, “Enrolling our first donor is a key milestone towards our goal of creating a bank of clinical-grade pluripotent human stem cells with the ability to immune-match millions of patients. It is extremely exciting to start this new phase of development, and I look forward to making new clinical-grade hpSC lines available to medical researchers around the world.”

ISCO maintains the world’s largest collection of research-grade human parthenogenetic stem cell (hpSC) lines which it uses along with its partners and collaborators to investigate cellular therapies for a number of incurable human diseases.

ISCO previously announced it had successfully obtained the necessary regulatory approvals for obtaining human oocytes, including Institutional Review Board (IRB) approval and Stem Cell Research Oversight (SCRO) committee approval. Today’s announcement marks the next phase of development as the Company is now positioned to begin producing new clinical-grade hpSC lines.

These new cell lines will be ISCO’s first hpSCs to be produced in the United States in accordance with Good Manufacturing Practice (cGMP) specifications. The new cGMP hpSC lines will be uniquely valuable in therapeutic research and clinical development as cells or tissue derived from such cells can be used in human clinical trials.

ISCO’s scientific discoveries have resulted in the development of a unique new type of pluripotent stem cells that possess a number of distinct advantages over other types of human pluripotent stem cells. ISCO uses unfertilized oocytes to create human “parthenogenetic” stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential production and benefits of stem cell lines, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

760-940-6383

Kenneth C. Aldrich

Chairman

kaldrich@intlstemcell.com

Simon Craw, Ph.D.

Vice President

sc@intlstemcell.com

or:

Lippert/Heilshorn & Associates

Don Markley (dmarkley@lhai.com)

310-691-7100

# # #

ISCO Scientists to Present Results of Recent Stem Cell Research on Central Nervous System and Liver Diseases at Annual Meeting of American Society of Gene and Cell Therapy

International Stem Cell Corporation (OTCBB: ISCO) announced today that two of its leading scientists, Vice President Dr. Ruslan Semechkin and Director of Research and Therapeutic Development Dr. Nikolay Turovets, will present the results of their most recent experiments on the therapeutic use of human parthenogenetic stem cells (hpSCs) at the 14th Annual Meeting of American Society of Gene and Cell Therapy in Seattle.

ISCO's breakthrough discoveries have resulted in a new type of pluripotent human stem cells with distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells. Like embryonic stem cells, hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike embryonic stem cells, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.

The data presented at the Seattle conference represents progress made in two specific areas: 1) the successful derivation of neuronal stem cell lines, which can potentially be used for treatment of degenerative diseases of the central nervous system (CNS), and 2) the differentiation of hpSCs towards liver cells and their progenitors.

Dr. Semechkin's oral presentation titled "Neural Stem Cells of Parthenogenetic Origin" will be on Thursday, May 19, 2011 at 4:15 pm.

Dr. Turovets poster presentation titled "An in vitro Analog of the Primitive Streak to Derive High-Purity Definitive Endoderm Lineages Uncontaminated with Undifferentiated Cells" will be on Saturday, May 21, 2011.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO & President, Lifeline Skin Care
ras@intlstemcell.com
Or:
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

see http://www.cellmedicine.com or http://www.stemnow.com

More here:
Adult Stem Cell Therapy for Multiple Sclerosis

see http://www.cellmedicine.com

Originally posted here:
Stem Cell Therapy for Critical Limb Ischemia

see http://www.cellmedicine.com

Go here to see the original:
Stem Cell Therapy for Multiple Sclerosis

Expat Insights breaks away a bit from learning, business and human development issues a bit ad focusses on health and wellness through a discussion on Stem Cell Therapy and Regenrative Medicines with Englishman James Thornton of the Philippines and Dr.

Excerpt from:
Regenerative Medicines

International Stem Cell Corporation (OTCBB: ISCO) today announced the Company's near-term marketing plans for products manufactured by its Lifeline Skin Care™ (Lifeline) subsidiary. Following the highly successful launch in late 2010 of Lifeline's first two products with sales that greatly exceeded expectations, Lifeline has now commenced a new phase in the marketing plan for its skin care products.

The first step in these initiatives is a series of briefings being conducted in New York City this week with editors at beauty magazines whose readership reflects the target user base for Lifeline's anti-aging skin care products. This will be followed by a series of targeted email offerings developed by Lifeline's marketing partner, The Mauldin Companies, culminating in a larger offering in June.

Lifeline's anti-aging products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetic experts. The first two products, a Day Serum and a Night Serum, both contain an extract from ISCO's proprietary human parthenogenetic stem cells which, in combination with vitamin complexes, provides major rejuvenating effects, including improvement in skin tone and elasticity, and improvement in the appearance of fine lines and wrinkles. These effects have been substantiated by clinical studies performed at industry-leading independent testing organizations.

Lifeline's premium product line includes the Recovery Night Moisture Serum and the Defensive Day Moisture Serum/SPF-15. These products are most commonly ordered together in a 2-pack, and can be purchased by visiting Lifeline's website athttp://www.lifelineskincare.com. The products are also available at selected luxury spas and physician's offices in the United States.

Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care, added that Lifeline plans to launch additional skin care products later this year, including an eye cream formulated with a proprietary stem cell derivative and a cleanser.

Lifeline is focusing its marketing on direct-to-consumer channels to highly targeted audiences with traditional print and media promotions planned for later in the year. The Company's goal is to generate favorable word-of-mouth through a network of satisfied customers, thereby building a community of users based on their shared experience of success with Lifeline's proprietary anti-aging products.

Ken Aldrich, Co-founder and Chairman of Lifeline's parent company, International Stem Cell Corporation, said, "The success of Lifeline Skin Care demonstrates that we can make a positive difference in people's lives today, while also providing an important source of revenue to support ISCO's development of stem cell therapies that may in the future result in treatment for many widespread human diseases."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction and marketing plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, ISCO
ras@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation (OTCBB: ISCO) today announced the Company's near-term marketing plans for products manufactured by its Lifeline Skin Care™ (Lifeline) subsidiary. Following the highly successful launch in late 2010 of Lifeline's first two products with sales that greatly exceeded expectations, Lifeline has now commenced a new phase in the marketing plan for its skin care products.

The first step in these initiatives is a series of briefings being conducted in New York City this week with editors at beauty magazines whose readership reflects the target user base for Lifeline's anti-aging skin care products. This will be followed by a series of targeted email offerings developed by Lifeline's marketing partner, The Mauldin Companies, culminating in a larger offering in June.

Lifeline's anti-aging products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetic experts. The first two products, a Day Serum and a Night Serum, both contain an extract from ISCO's proprietary human parthenogenetic stem cells which, in combination with vitamin complexes, provides major rejuvenating effects, including improvement in skin tone and elasticity, and improvement in the appearance of fine lines and wrinkles. These effects have been substantiated by clinical studies performed at industry-leading independent testing organizations.

Lifeline's premium product line includes the Recovery Night Moisture Serum and the Defensive Day Moisture Serum/SPF-15. These products are most commonly ordered together in a 2-pack, and can be purchased by visiting Lifeline's website athttp://www.lifelineskincare.com. The products are also available at selected luxury spas and physician's offices in the United States.

Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care, added that Lifeline plans to launch additional skin care products later this year, including an eye cream formulated with a proprietary stem cell derivative and a cleanser.

Lifeline is focusing its marketing on direct-to-consumer channels to highly targeted audiences with traditional print and media promotions planned for later in the year. The Company's goal is to generate favorable word-of-mouth through a network of satisfied customers, thereby building a community of users based on their shared experience of success with Lifeline's proprietary anti-aging products.

Ken Aldrich, Co-founder and Chairman of Lifeline's parent company, International Stem Cell Corporation, said, "The success of Lifeline Skin Care demonstrates that we can make a positive difference in people's lives today, while also providing an important source of revenue to support ISCO's development of stem cell therapies that may in the future result in treatment for many widespread human diseases."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction and marketing plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, ISCO
ras@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

http://www.cellmedicine.com

See more here:
Stem Cell Therapy for Multiple Sclerosis (MS patient)

CARLSBAD, Calif. (May 05, 2011) - At the annual shareholders meeting of International Stem Cell Corporation (OTCBB:ISCO) on May 3, 2011, Kenneth Aldrich, Chairman and co-founder of ISCO conducted a presentation to shareholders that included the following remarks:

Good morning to all our shareholders and friends of ISCO. Let me make just a few comments about where we are and the progress we have made over the last year. All of the developments and news I will discuss were announced in the past 12 months, but with the passage of time it is easy to lose track of how much progress ISCO has actually made. I won’t mention everything—we don’t have that much time, but some highlights will, I hope, help put these recent achievements into perspective.

A little less than a year ago, in June 2010, our first parthenogenetic patent application was formally approved by the US Patent Office. More applications are pending, but this approval established ISCO as the lawful owner of the rights to produce human stem cell lines through parthenogenesis. That is a platform on which we expect to build for a long time.

Also in June we eliminated all of our outstanding corporate debt and we remain debt free.

In July we announced the signing of a distribution contract with Sristi Biosciences, a major seller of research products in India, which continues the international commercial expansion of our Lifeline Cell Technology^® brand.

In October we announced the first steps toward the formation of a major funded collaboration in India with Insight Bioventures India Private Limited (IBVI) to develop treatments for corneal damage and retinal disease. Planning for that work is ongoing and the Executive Director of Insight Bioventures has flown in from India to meet with us today, so we remain very optimistic about this project.

In November, we presented the results of scientific studies demonstrating a new and better method for differentiating our parthenogenetic cells into liver cells, a critical step toward using them to treat liver disease.

In November and December we launched the first test marketing runs of our new skin crème products, first to our own shareholders and friends, then to a select mailing list developed by our marketing partner, John Mauldin. Those resulted in sales of over 7,000 bottles of our new products.

In December we established $25 million financing commitment that provides access to capital on an as-needed basis over a three year period, but never requires the sale of stock unless we think it will benefit the company and its shareholders. This agreement provides us a high degree of flexibility in meeting our financial needs.

In January 2011 we announced publication of peer-reviewed studies further validating the functional equivalency of our parthenogenetic stem cells with embryonic stem cells. These studies confirm our ability to benefit from much of the millions of dollars of research on embryonic stem cells over the last decade. In short, we have a running start in the search for cures.

Throughout the year we have made steady progress in development of liver cells and liver precursor cells, culminating in an announcement in April of this year that we had successfully completed the first in a series of pre-clinical tests of parthenogenetically derived liver cells.

Last, but by no means least, we have received the necessary approvals for creating new Parthenogenetic Stem Cell Lines in the United States. These will be clinical grade lines suitable for human trials, and are the first major step in this country to begin building a “Bank” of stem cells enabling the matching of immune systems of millions of people worldwide, with the potential to eliminate or reduce the harmful effects of immune suppressing drugs that would normally have to be used with stem cell transplant procedures.

All of these news stories and more are available on our website along with presentations we have made recently to investors in the US and Europe. On behalf of the Board of Directors and everyone at ISCO, I thank you for your support.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact:

International Stem Cell Corporation

Kenneth C Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

# # #